Information Provided By:
Fly News Breaks for February 2, 2016
RDUS
Feb 2, 2016 | 08:19 EDT
After meeting with Radius Health CEO Bob Ward, JPMorgan analyst Jessica Fye says the recent pullback in the shares is overdone. The stock now reflects low commercial expectations for abaloparatide, Fye tells investors in a research note. She believes the osteoporosis market has the capacity to support multiple potential blockbuster drugs. The analyst keeps an Overweight rating on Radius with an $88 price target.
News For RDUS From the Last 2 Days
There are no results for your query RDUS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.